Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.
Sign Up to like & getrecommendations! Published in 2023 at "Dermatology online journal"
DOI: 10.5070/d329160209
Abstract: Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison… read more here.
Keywords: dermatology; ritonivir covid; nirmatrelvir ritonivir; covid possible ... See more keywords